Blue Trust Inc. Buys 257 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Blue Trust Inc. lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 24.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 1,307 shares of the specialty pharmaceutical company’s stock after acquiring an additional 257 shares during the quarter. Blue Trust Inc.’s holdings in Jazz Pharmaceuticals were worth $139,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. International Assets Investment Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $7,201,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Jazz Pharmaceuticals by 29.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,113 shares of the specialty pharmaceutical company’s stock worth $4,811,000 after buying an additional 8,814 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 15.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 4,707 shares of the specialty pharmaceutical company’s stock worth $579,000 after buying an additional 631 shares during the last quarter. abrdn plc boosted its stake in shares of Jazz Pharmaceuticals by 442.2% in the 4th quarter. abrdn plc now owns 56,230 shares of the specialty pharmaceutical company’s stock worth $6,916,000 after buying an additional 45,860 shares during the last quarter. Finally, Duality Advisers LP boosted its stake in shares of Jazz Pharmaceuticals by 35.8% in the 4th quarter. Duality Advisers LP now owns 25,641 shares of the specialty pharmaceutical company’s stock worth $3,154,000 after buying an additional 6,758 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 3.0 %

Shares of JAZZ stock opened at $114.24 on Tuesday. The company’s fifty day simple moving average is $108.89 and its two-hundred day simple moving average is $113.24. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $146.70. The stock has a market capitalization of $7.20 billion, a price-to-earnings ratio of 23.55, a PEG ratio of 1.76 and a beta of 0.58.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research analyst reports. Needham & Company LLC cut their target price on Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. UBS Group dropped their price objective on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Piper Sandler dropped their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.